About coagulation factor ix
Plasma-derived coagulation factor IX
Used for
- Prevention and treatment of bleeding in haemophilia B
- Bleeding control during surgery in haemophilia B
Usual adult dose
Intravenous dosing is individualized by body weight, desired factor level, and bleeding severity; commonly 20–40 IU/kg initially.
Usual dose in children
Similar weight-based dosing to adults; individualized by bleeding severity and measured factor IX levels.
Common side effects
- Headache
- Fever or chills
- Nausea
- Injection-site reactions
Important warnings
- Allergic reactions, including severe reactions, can occur.
- Inhibitory antibodies may develop and reduce treatment effectiveness.
- Blood clots are possible, especially with high doses or clotting risk factors.
- Derived from human plasma; screening and processing reduce, but cannot eliminate, infection risk.
Pregnancy
Use only when clearly needed; pregnancy experience is limited. Haemophilia B treatment may require specialist monitoring.
Breastfeeding
Information is limited; use when clinically needed, with advice from the treating clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.